Tier 3 — preclinical
Deciphering the role of SIRT6 in suppressing the AMPK-mTOR-TFEB axis: regulation of autophagy activation in HCC
Cancer Gene Therapy
2026
33(4):440-455
Bibliography
- PubMed
- PMID 41957523
- Funding
- Supported by NCI grants P50 CA217674 and R01 CA237327 and National Research Foundation of Korea grants 2017R1A5A2015061 and 2021R1A2C2013505.
- Competing interests
- Authors declared no competing interests.
Study snapshot
| Design | Mechanistic HCC study using molecular perturbation, cell models, animal experiments and human tissues. |
|---|---|
| Model | Hepatocellular carcinoma cells, animal tumor models and human HCC tissue. |
| Sample | Multiple experiments; exact group sizes vary across assays. |
| Intervention | SIRT6 upregulation and pathway perturbation of AMPK-mTOR-TFEB. |
| Duration | Model-specific experimental durations. |
| Endpoints | AMPK activation; mTOR suppression; TFEB nuclear translocation; Autophagy; Cell proliferation and death; Tumor-suppressive effects |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
